IgAV-N in children: High risk, low evidence. A path for better trials

Written by The Life Science Feed Editorial Team · Published 28 July 2026 · Edited by Mara Voss

IgA vasculitis (IgAV) is an autoimmune disease affecting small vessels in the skin, joints, gastrointestinal tract, and kidneys. When associated with nephritis (IgAV-N), the long-term prognosis can include kidney failure, a particularly concerning outcome in pediatric populations. The current evidence base for managing IgAV-N is sparse, leading to significant variations in treatment approaches and, consequently, suboptimal patient outcomes.1

KEY TAKEAWAYS

- The Pivot: An international workshop established a pathway for developing high-quality clinical trial evidence for IgAV-N, acknowledging similarities with IgA nephropathy.
- The Data: 53 attendees from 13 countries reached consensus on focusing initial trials on patients at greatest risk of kidney failure.
- The Action: Clinicians should advocate for and participate in age-inclusive trials, prioritizing patient-reported outcomes and systemic disease secondary endpoints.

IgA vasculitis nephritis (IgAV-N) represents a significant challenge in pediatric nephrology, given its potential to progress to end-stage kidney disease. Despite the severity of this complication, robust, evidence-based clinical studies guiding treatment are notably absent. This gap in knowledge contributes directly to the observed variability in clinical practice and the inconsistent outcomes for children with IgAV-N.1

The field of IgA nephropathy (IgAN) has seen a surge of new, efficacious treatments. This progress offers a template and potential therapeutic avenues for IgAV-N, prompting a multiprofessional international collaborative workshop to address the existing research deficit. The workshop convened to identify the specific barriers hindering the development of high-quality evidence for patients with IgAV-N.1

Defining the Research Landscape

A diverse group of 53 attendees from 13 countries participated in the workshop. This group included a broad spectrum of professional backgrounds, from professors (32%) and mid-career doctors (19%) to lay attendees, ensuring a comprehensive perspective on the disease and its impact. The participants worked with predefined aims to extract key themes and develop a concrete action plan for future research.1

A central point of consensus emerged regarding the fundamental similarities between adult and pediatric IgAV-N. Participants agreed that the organs involved, the underlying pathophysiology, and the histological features of the disease largely overlap across age groups. This shared understanding extends to the likely response to treatment, suggesting that

insights gained from adult studies could, in many cases, be extrapolated or adapted for pediatric populations.1
But, the workshop also highlighted critical differences. Children with IgAV-N often experience a greater degree of spontaneous improvement compared to adults. Conversely, some pediatric populations face worse kidney outcomes, underscoring the need for careful stratification and targeted interventions. These distinctions are vital for designing trials that accurately reflect the natural history and treatment responses in children.1

Prioritizing Patients and Trial Design

The collaborative workshop reached a firm agreement: initial clinical trials for IgAV-N should primarily focus on patients at the greatest risk of kidney failure. This strategic prioritization aims to address the most urgent clinical need and maximize the impact of early research efforts. Identifying these high-risk patients will be crucial for trial recruitment and for demonstrating clear clinical benefit.1
Several important considerations for trial design emerged from the discussions. Participants emphasized the need for a clear diagnostic classification for adult-onset IgAV, which would help standardize patient cohorts across studies. The inclusion of observational data was also deemed valuable, providing real-world context and complementing randomized controlled trial findings.1
The scientific similarity between IgAV-N and IgA nephropathy (IgAN) was a recurring theme. This similarity suggests that treatments proven effective in IgAN might hold promise for IgAV-N, potentially accelerating drug development. Future trials should explore this overlap, perhaps by adapting protocols or endpoints from successful IgAN studies.1
An age-inclusive approach to trial design was a key recommendation. This means developing protocols that can enroll both children and adults, allowing for direct comparisons and a more comprehensive understanding of treatment effects across the lifespan. Such an approach would also facilitate larger trial populations, increasing statistical power.1
Beyond kidney-specific outcomes, the workshop stressed the importance of including systemic disease secondary endpoints. IgAV affects multiple organ systems, and a holistic evaluation of treatment efficacy must account for improvements in skin, joint, and gastrointestinal manifestations. This broader perspective ensures that trials capture the full clinical benefit for patients.1
Finally, the inclusion of patient-reported outcomes (PROs) was considered essential. PROs provide invaluable insights into the patient experience, capturing aspects of health and quality of life that traditional clinical endpoints might miss. For children, this could involve age-appropriate questionnaires or proxy reporting from parents, ensuring their voice is heard in assessing treatment success.1

The Path Forward for High-Quality Evidence

The workshop proceedings outlined a clear, expert-informed pathway to generating high-quality evidence for IgAV-N. This pathway emphasizes collaboration, standardized diagnostics, and patient-centered trial design. The goal is to move beyond the current variability in care and establish robust, evidence-based guidelines that improve outcomes for all patients, especially children, who face significant long-term risks.1
The consensus on the similarities between adult and pediatric IgAV-N, while acknowledging key differences, provides a foundation for more integrated research efforts. This could lead to more efficient trial recruitment and a faster translation of research into clinical practice. The focus on high-risk patients ensures that initial resources target those most in need of effective therapies.1

Still, the implementation of these recommendations will require sustained effort and continued international collaboration. Developing age-inclusive trials, incorporating diverse endpoints, and ensuring patient voice are complex undertakings. But, the framework provided by this workshop offers a clear roadmap for the research community. Clinicians seeking to deepen their understanding of pediatric conditions and their management might find the Oxford Handbook of Paediatrics a useful resource for quick reference.1

The workshop did not detail specific drug candidates or trial protocols, but rather laid the groundwork for how such trials should be conceived and executed. This foundational work is critical for ensuring that future studies are well-designed, ethical, and capable of producing actionable results. Without this consensus on methodology and priorities, individual trials risk being fragmented and incomparable.1

The emphasis on patient-reported outcomes is particularly important in a chronic disease like IgAV-N, where quality of life can be significantly impacted. Measuring how patients feel and function provides a more complete picture of treatment benefit than laboratory values or biopsy results alone. This patient-centric approach aligns with modern clinical trial best practices.1

The open-label design of many previous observational studies in IgAV-N is an obvious caveat when considering the strength of existing evidence. Future trials will need to adopt more rigorous methodologies, including blinding and randomization, to provide definitive answers on treatment efficacy. The workshop's focus on high-quality evidence directly addresses this historical limitation.1

The workshop proceedings did not quantify the precise risk of kidney failure in different pediatric populations, nor did they specify exact criteria for identifying "greatest risk" patients. This remains an area requiring further definition and consensus, likely through prospective observational studies or registry data. The lack of specific diagnostic criteria for adult-onset IgAV also presents a challenge that needs resolution for consistent trial enrollment.1

CLINICAL IMPLICATIONS

The current variability in managing pediatric IgAV-N is unacceptable, driven by a lack of robust evidence. This international consensus provides a much-needed framework, pushing the field towards standardized, high-quality clinical trials. GPs and specialists should recognize that current treatment decisions often rely on expert opinion rather than definitive data, highlighting the urgency of these research efforts.

The explicit recognition of similarities between IgAV-N and IgA nephropathy is a practical step. It opens the door for repurposing or adapting therapies already showing promise in IgAN, potentially accelerating drug development for children. But, the noted differences in spontaneous improvement and kidney outcomes in children mean direct extrapolation without specific pediatric data remains risky.

Prioritizing trials for children at highest risk of kidney failure is a pragmatic approach, ensuring that limited research resources target the most vulnerable. Clinicians should be prepared to identify and refer these patients for trial participation, understanding that patient-reported outcomes will be as critical as traditional clinical endpoints. This shift demands a more holistic assessment of treatment benefit.

The call for age-inclusive trial designs is a welcome move, fostering a more unified approach to IgAV-N research. This could lead to more comprehensive data sets and a clearer understanding of disease progression and treatment response across the lifespan. It also means that clinicians treating adults with IgAV-N may soon benefit from data generated in pediatric cohorts, and vice-versa.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Oni L, Smith R, Ozen S. A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop. Kidney Int Rep. 2026.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com